Table 1 Baseline characteristics and patient status at randomisation
Baseline variables | Intervention (n = 36) | Control (n = 38) |
|---|---|---|
Age, years, median | 60 | 59 |
(1st, 3rd quartile; min–max) | (44, 69; 25–85) | (43, 72; 27–80) |
Sex, male/female | 21/15 | 26/12 |
Primary diagnosis, number of patients | ||
Cardiovascular | 8 | 5 |
Respiratory | 3 | 9 |
Gastrointestinal | 14 | 15 |
Renal | 0 | 1 |
Trauma | 3 | 1 |
Other | 8 | 7 |
APACHE II score, median | 20 | 23 |
(1st, 3rd quartile; min–max) | (11, 24; 0–31) | (17, 26; 0–38) |
Charlson comorbidity index, median | 1 | 1 |
(1st, 3rd quartile; min–max) | (0, 2; 0–5) | (0, 2; 0–7) |
SOFA score for first 24 hours, median | 7 | 8 |
(1st, 3rd quartile; min–max) | (5, 11; 2–16) | (5, 9; 1–16) |
Time, hours from intubation to start of monitoring, median | 4.0 | 4.9 |
(1st, 3rd quartile; min–max) | (2.1, 6.2; 1.0–12.0) | (3.5, 7.7; 0.7– 1.8) |
RI at start of intervention period, median | 16 | 18 |
(1st, 3rd quartile; min–max) | (0, 55; 0–100) | (0, 42; 0–100) |
Red, n (%) | 19 (54.3 %) | 20 (54.1 %) |
Amber, n (%) | 5 (14.3 %) | 8 (21.6 %) |
Green, n (%) | 11 (31.4 %) | 9 (24.3 %) |
No value, n (%)a | 1 (2.8 %) | 1 (2.6 %) |
RASS score at start of intervention period, median | −3 | −4 |
(1st, 3rd quartile; min to max) | (−4, −2; −5 to +0) | (−4, −3; −5 to +2) |
Total alfentanil dose, mg, prior to monitoring, median | 1.75 | 3.00 |
(1st, 3rd quartile; min–max) | (0.75, 5.25; 0.00–14.00) | (1.00, 7.50; 0.00–17.50) |